

Kindly replace pending claims 24, 25 and 30 with the following claims:

B4 24. (Amended) A method of treating wounds by increasing coagulation, said method comprising administering to a mammalian subject having a wound a therapeutic amount of a composition comprising a polypeptide of claim 10 and a pharmaceutically acceptable carrier, wherein said wound is healed.

B5 28. (Twice Amended) An isolated polypeptide having prothrombinase activity comprising an amino acid sequence which is at least 99% identity to the amino acid sequence of SEQ ID NO: 9.

B6 30. (Amended) An isolated polypeptide comprising SEQ ID NO: 9, wherein said polypeptide has prothrombinase activity.

REMARKS

Claims 10, 11, 24, 25, 30, and 31 are pending. Examiner has rejected claims 20, 24, 25, and 30 under 35 U.S.C. §112, 2nd paragraph. Examiner has objected to the use of single letter code for amino acids in the specification. Applicants have amended the specification to replace the single letter code with three letter codes in substitute pages 112-114, submitted herewith.

Applicants disclaim priority as a continuation-in-part of prior application no. 09/552,317, filed 04/25/2000, Attorney Docket No. 784CIP, which is a continuation-in-part of prior application no. 09/488,725, filed 01/21/2000, Attorney Docket No. 784, as previously claimed in the preliminary amendment filed with the transmittal letter of June 17, 2000, and submit a new transmittal letter reflecting this disclaimer.

Applicants respectfully submit that the all pending claims are in a condition for allowance, and request a Notice of Allowance. The undersigned can be reached at 408-746-4536 if the Examiner wishes to discuss the response.

An early action on the merits is respectfully requested.

The Commissioner is hereby authorized to charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 501169.

Respectfully submitted,